Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641646 | 0.95 | GRB2 (0.48) | GRB2XIAPCALCRLCAPN1NMUR2 | |
| SCHEMBL29641620 | 0.86 | KDM1A (0.45) | XIAPCALCRLCAPN1NMUR2KEAP1 | |
| SCHEMBL29641660 | 0.85 | CALCRL (0.44) | GRB2XIAPCALCRLCAPN1NMUR2 | |
| SCHEMBL30150556 | 0.83 | BACE1 (0.49) | XIAPCALCRLAGTR2AGTR1 | |
| SCHEMBL29641790 | 0.83 | GRB2 (0.49) | GRB2CALCRLCAPN1AGTR2AGTR1 | |
| SCHEMBL29641650 | 0.83 | GRB2 (0.49) | GRB2CALCRLCAPN1AGTR2AGTR1 | |
| SCHEMBL30150546 | 0.83 | GRB2 (0.52) | GRB2XIAPCALCRLCAPN1CTSB | |
| SCHEMBL30311207 | 0.83 | XIAP (0.53) | GRB2XIAPCALCRLCAPN1CMA1 | |
| SCHEMBL29641846 | 0.82 | GRB2 (0.51) | GRB2XIAPCAPN1CTSBCMA1 | |
| SCHEMBL6524705 | 0.81 | BACE1 (0.48) | GRB2XIAPCALCRLNMUR2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409709-A1 | LABYRINTHIN-BASED PEPTIDES FOR CANCER IMMUNOTHERAPIES AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS USA LTD (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220089719-A1 | CONSTRUCTS TARGETING LABYRINTHIN OR A PORTION THEREOF AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS (USA) LIMITED (US) | 2022-03-24 | — | — | US | disclosed |